Escaping the immune system: How the malaria parasite makes vaccine development a challenge

Trends in Parasitology

Volumn 29, Issue 12, 2013, Pages 612-622

  Stanisic, Danielle I ^a   Barry, Alyssa E ^b   Good, Michael F ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Immune evasion; Immunity; Immunomodulation; Malaria; Vaccine

Indexed keywords

B CELL ACTIVATING FACTOR; CIRCUMSPOROZOITE PROTEIN; DNA; GAMMA INTERFERON; MALARIA VACCINE; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; TOXIN;

CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; HAPLOTYPE; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INNATE IMMUNITY; LIFE CYCLE; MACROPHAGE; MEMORY T LYMPHOCYTE; MEROZOITE; NATURAL KILLER CELL; PARASITE IMMUNITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; REVIEW; VIRUS LIKE AGENT;

IMMUNE EVASION; IMMUNITY; IMMUNOMODULATION; MALARIA; VACCINE;

ANIMALS; HOST-PARASITE INTERACTIONS; HUMANS; IMMUNE SYSTEM; MALARIA; MALARIA VACCINES; PLASMODIUM;

EID: 84888135119     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2013.10.001     Document Type: Review

References (151)

1. World Health Organisation World Malaria Report 2012 2012, World Health Organisation.
2. Freund J., et al. Immunization of Rhesus monkeys against malarial infection (P. knowlesi) with killed parasites and adjuvants. Science 1945, 102:202-204.
3. Freund J., et al. Immunization against malaria: vaccination of ducks with killed parasites incorporated with adjuvants. Science 1945, 102:200-202.
4. Nussenzweig R.S., et al. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
5. Clyde D.F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 1975, 24:397-401.
6. Kemp D.J., et al. Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:3787-3791.
7. Ellis J., et al. Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 1983, 302:536-538.
8. Stanisic D.I., et al. Robert Koch redux: malaria immunology in Papua New Guinea. Parasite Immunol. 2010, 32:623-632.
9. Doolan D., et al. Acquired immunity to malaria. Clin. Microbiol. Rev. 2009, 22:13-36.
10. + regulatory T cells. Int. J. Biol. Sci. 2011, 7:1311-1322.
11. Artavanis-Tsakonas K., et al. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin. Exp. Immunol. 2003, 133:145-152.
12. Stevenson M.M., Riley E.M. Innate immunity to malaria. Nat. Rev. Immunol. 2004, 4:169-180.
13. Potocnjak P., et al. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 1980, 151:1504-1513.
14. Hollingdale M.R., et al. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 1984, 132:909-913.
15. Offeddu V., et al. Naturally acquired immune responses against Plasmodium falciparum sporozoites and liver infection. Int. J. Parasitol. 2012, 42:535-548.
16. + T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:573-576.
17. + T cells against malaria liver stages: implications for vaccine development. Mem. Inst. Oswaldo Cruz 2011, 106(Suppl. 1):172-178.
18. Zevering Y., et al. Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:6118-6122.
19. Scheller L.F., Azad A.F. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:4066-4068.
20. + T cell responses against malaria liver stage parasites. PLoS Pathog. 2010, 6:e1000877.
21. + T cells induced by malaria sporozoites. PLoS ONE 2011, 6:e15948.
22. Schmidt N.W., et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14017-14022.
23. Good M.F., Doolan D.L. Malaria vaccine design: immunological considerations. Immunity 2010, 33:555-566.
24. Guilbride D.L., et al. Malaria's deadly secret: a skin stage. Trends Parasitol. 2012, 28:142-150.
25. Cohen S., et al. Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192:733-737.
26. Osier F.H., et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect. Immun. 2008, 76:2240-2248.
27. Trieu A., et al. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol. Cell. Proteomics 2011, 10. M111.007948.
28. Crompton P.D., et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6958-6963.
29. Barry A.E., et al. The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area. Mol. Cell. Proteomics 2011, 10. M111.008326.
30. Murungi L.M., et al. A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine 2013, 31:3936-3942.
31. Fowkes F.J., et al. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med. 2010, 7:e1000218.
32. Akpogheneta O.J., et al. Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect. Immun. 2008, 76:1748-1755.
33. Kinyanjui S.M., et al. IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar. J. 2007, 6:82.
34. Scholzen A., Sauerwein R.W. How malaria modulates memory: activation and dysregulation of B cells in Plasmodium infection. Trends Parasitol. 2013, 29:252-262.
35. Portugal S., et al. Young lives lost as B cells falter: what we are learning about antibody responses in malaria. J. Immunol. 2013, 190:3039-3046.
36. Lamb T.J., et al. Insights into the immunopathogenesis of malaria using mouse models. Expert Rev. Mol. Med. 2006, 8:1-22.
37. Wykes M.N., Good M.F. What have we learnt from mouse models for the study of malaria?. Eur. J. Immunol. 2009, 39:2004-2007.
38. Taylor-Robinson A.W., et al. The role of TH1 and TH2 cells in a rodent malaria infection. Science 1993, 260:1931-1934.
39. Amante F.H., Good M.F. Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunol. 1997, 19:111-126.
40. + T cells from non-exposed donors. Parasite Immunol. 1994, 16:579-586.
41. Elliott S.R., et al. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect. Immun. 2005, 73:2478-2485.
42. Pombo D.J., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360:610-617.
43. Grun J.L., Weidanz W.P. Antibody-independent immunity to reinfection malaria in B-cell-deficient mice. Infect. Immun. 1983, 41:1197-1204.
44. Brake D.A., et al. Adoptive protection against Plasmodium chabaudi adami malaria in athymic nude mice by a cloned T cell line. J. Immunol. 1988, 140:1989-1993.
45. Amante F.H., et al. Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malaria. J. Immunol. 2010, 185:3632-3642.
46. + dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14509-14514.
47. + T cells in protective immunity against murine blood-stage infection with Plasmodium yoelii 17XL strain. Eur. J. Immunol. 2010, 40:1053-1061.
48. Hansen D.S., Schofield L. Natural regulatory T cells in malaria: host or parasite allies?. PLoS Pathog. 2010, 6:e1000771.
49. Finney O.C., et al. Regulatory T cells in malaria - friend or foe?. Trends Immunol. 2010, 31:63-70.
50. Freitas do Rosario A.P., et al. Gradual decline in malaria-specific memory T cell responses leads to failure to maintain long-term protective immunity to Plasmodium chabaudi AS despite persistence of B cell memory and circulating antibody. J. Immunol. 2008, 181:8344-8355.
51. Stephens R., Langhorne J. Effector memory Th1 CD4 T cells are maintained in a mouse model of chronic malaria. PLoS Pathog. 2010, 6:e1001208.
52. Stephens R., et al. Homeostatic proliferation and IL-7Rα expression do not correlate with enhanced T cell proliferation and protection in chronic mouse malaria. PLoS ONE 2011, 6:e26686.
53. Wipasa J., et al. Short-lived IFN-γ effector responses, but long-lived IL-10 memory responses, to malaria in an area of low malaria endemicity. PLoS Pathog. 2011, 7:e1001281.
54. + malaria-specific responses from non-exposed donors. Int. Immunol. 1992, 4:985-994.
55. Barry A.E., et al. Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS ONE 2009, 4:e8497.
56. Chan J.A., et al. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. J. Clin. Invest. 2012, 122:3227-3238.
57. Smith J.D., et al. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 1995, 82:101-110.
58. Su X.Z., et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 1995, 82:89-100.
59. Barry A.E., et al. Population genomics of the immune evasion (var) genes of Plasmodium falciparum. PLoS Pathog. 2007, 3:e34.
60. Cham G.K., et al. Hierarchical, domain type-specific acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 in Tanzanian children. Infect. Immun. 2010, 78:4653-4659.
61. Cham G.K., et al. Sequential, ordered acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 domains. J. Immunol. 2009, 183:3356-3363.
62. Sagara I., et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009, 27:3090-3098.
63. Ogutu B.R., et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 2009, 4:e4708.
64. Sirima S.B., et al. Protection against malaria by MSP3 candidate vaccine. N. Engl. J. Med. 2011, 365:1062-1064.
65. Takala S.L., et al. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med. 2007, 4:e93.
66. Takala S.L., et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci. Transl. Med. 2009, 1:2ra5.
67. Bejon P., et al. The induction and persistence of T cell IFN-γ responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J. Immunol. 2007, 179:4193-4201.
68. Ho M., et al. Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. J. Infect. Dis. 1986, 153:763-771.
69. Wykes M.N., Good M.F. What really happens to dendritic cells during malaria?. Nat. Rev. Microbiol. 2008, 6:864-870.
70. Wykes M.N., et al. Plasmodium strain determines dendritic cell function essential for survival from malaria. PLoS Pathog. 2007, 3:e96.
71. Wykes M.N., et al. Systemic tumor necrosis factor generated during lethal Plasmodium infections impairs dendritic cell function. J. Immunol. 2007, 179:3982-3987.
72. Sponaas A., et al. Malaria infection changes the ability of splenic dendritic cell populations to stimulate antigen-specific T cells. J. Exp. Med. 2006, 203:1427-1433.
73. Lundie R.J., et al. Blood-stage Plasmodium berghei infection leads to short-lived parasite-associated antigen presentation by dendritic cells. Eur. J. Immunol. 2010, 40:1674-1681.
74. Urban B.C., et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999, 400:73-77.
75. Arama C., et al. Interethnic differences in antigen-presenting cell activation and TLR responses in Malian children during Plasmodium falciparum malaria. PLoS ONE 2011, 6:e18319.
76. Giusti P., et al. Plasmodium falciparum-infected erythrocytes and β-hematin induce partial maturation of human dendritic cells and increase their migratory ability in response to lymphoid chemokines. Infect. Immun. 2011, 79:2727-2736.
77. + regulatory T cells, dendritic cells, and circulating cytokines in uncomplicated malaria: do different parasite species elicit similar host responses?. Infect. Immun. 2010, 78:4763-4772.
78. Urban B.C., et al. Peripheral blood dendritic cells in children with acute Plasmodium falciparum malaria. Blood 2001, 98:2859-2861.
79. Urban B.C., et al. Fatal Plasmodium falciparum malaria causes specific patterns of splenic architectural disorganization. Infect. Immun. 2005, 73:1986-1994.
80. Pichyangkul S., et al. Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J. Immunol. 2004, 172:4926-4933.
81. Urban B.C., et al. The frequency of BDCA3-positive dendritic cells is increased in the peripheral circulation of Kenyan children with severe malaria. Infect. Immun. 2006, 74:6700-6706.
82. Elliott S.R., et al. Inhibition of dendritic cell maturation by malaria is dose dependent and does not require Plasmodium falciparum erythrocyte membrane protein 1. Infect. Immun. 2007, 75:3621-3632.
83. Woodberry T., et al. Low-level Plasmodium falciparum blood-stage infection causes dendritic cell apoptosis and dysfunction in healthy volunteers. J. Infect. Dis. 2012, 206:333-340.
84. Pinzon-Charry A., et al. Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. J. Exp. Med. 2013, 210:1635-1646.
85. Millington O.R., et al. Malaria impairs T cell clustering and immune priming despite normal signal 1 from dendritic cells. PLoS Pathog. 2007, 3:1380-1387.
86. Millington O.R., et al. Suppression of adaptive immunity to heterologous antigens during Plasmodium infection through hemozoin-induced failure of dendritic cell function. J. Biol. 2006, 5:5.
87. Wykes M.N., et al. Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11205-11210.
88. + T cells in malaria infection. J. Exp. Med. 2002, 195:881-892.
89. + T cells adoptively transferred into recipient mice after challenge with homologous parasite. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:1715-1720.
90. Wipasa J., et al. Apoptotic deletion of Th cells specific for the 19-kDa carboxyl-terminal fragment of merozoite surface protein 1 during malaria infection. J. Immunol. 2001, 167:3903-3909.
91. Butler N.S., et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat. Immunol. 2012, 13:188-195.
92. Illingworth J., et al. Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J. Immunol. 2013, 190:1038-1047.
93. Crotty S., et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 2003, 171:4969-4973.
94. Dorfman J.R., et al. B cell memory to 3 Plasmodium falciparum blood-stage antigens in a malaria-endemic area. J. Infect. Dis. 2005, 191:1623-1630.
95. Wipasa J., et al. Long-lived antibody and B cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog. 2010, 6:e1000770.
96. Weiss G.E., et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J. Immunol. 2009, 183:2176-2182.
97. Weiss G.E., et al. A positive correlation between atypical memory B cells and Plasmodium falciparum transmission intensity in cross-sectional studies in Peru and Mali. PLoS ONE 2011, 6:e15983.
98. Nduati E., et al. The plasma concentration of the B cell activating factor is increased in children with acute malaria. J. Infect. Dis. 2011, 204:962-970.
99. Hill A.V. Vaccines against malaria. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2011, 366:2806-2814.
100. Casares S., et al. The RTS,S malaria vaccine. Vaccine 2010, 28:4880-4894.
101. Agnandji S.T., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 2011, 365:1863-1875.
102. Olotu A., et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 2013, 368:1111-1120.
103. Genton B., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 2002, 185:820-827.
104. Palacpac N.M., et al. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. PLoS ONE 2013, 8:e64073.
105. Snounou G., et al. The Plasmodium sporozoite survives RTS,S vaccination. Trends Parasitol. 2005, 21:456-461.
106. Good M.F. Our impasse in developing a malaria vaccine. Cell. Mol. Life Sci. 2011, 68:1105-1113.
107. Dutta S., et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE 2009, 4:e8138.
108. Polhemus M.E., et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 2009, 4:e6465.
109. Miura K., et al. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. Infect. Immun. 2013, 81:1491-1501.
110. Makobongo M.O., et al. The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2628-2633.
111. Culleton R., et al. Linkage group selection: rapid gene discovery in malaria parasites. Genome Res. 2005, 15:92-97.
112. Martinelli A., et al. A genetic approach to the de novo identification of targets of strain-specific immunity in malaria parasites. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:814-819.
113. McCarthy J.S., Good M.F. Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum. Vaccin. 2010, 6:114-123.
114. Luke T.C., Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 2003, 206:3803-3808.
115. Seder R.A., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
116. Roestenberg M., et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 2009, 361:468-477.
117. Roestenberg M., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377:1770-1776.
118. Inoue M., et al. The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development. Int. J. Parasitol. 2012, 42:859-870.
119. Butler N.S., et al. Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol. 2012, 33:247-254.
120. Purcell L.A., et al. Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge. Vaccine 2008, 26:4880-4884.
121. Butler N.S., et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011, 9:451-462.
122. Annoura T., et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 2012, 30:2662-2670.
123. + T cell responses against blood-stage malaria in mice. J. Clin. Invest. 2010, 120:2967-2978.
124. Aly A.S., et al. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice. Cell. Microbiol. 2010, 12:930-938.
125. Good M., et al. Cross-species malaria immunity induced by chemically attenuated parasites. J. Clin. Invest. 2013, 123:3353-3362.
126. Kemp K., et al. Cytokine production and apoptosis among T cells from patients under treatment for Plasmodium falciparum malaria. Clin. Exp. Immunol. 2002, 127:151-157.
127. Ing R., Stevenson M.M. Dendritic cell and NK cell reciprocal cross talk promotes γ interferon-dependent immunity to blood-stage Plasmodium chabaudi AS infection in mice. Infect. Immun. 2009, 77:770-782.
128. Newman K.C., et al. Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-γ responses to malaria. PLoS Pathog. 2006, 2:e118.
129. Inoue S., et al. Enhancement of dendritic cell activation via CD40 ligand-expressing γδ T cells is responsible for protective immunity to Plasmodium parasites. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:12129-12134.
130. + T cells and the recognition of MHC class I molecules. Immunology 1996, 89:405-412.
131. D'Ombrain M., et al. γδ T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-γ responses to Plasmodium falciparum malaria. Eur. J. Immunol. 2007, 37:1864-1873.
132. Artavanis-Tsakonas K., Riley E. Innate immune response to malaria: rapid induction of IFN-γ from human NK cells by live Plasmodium falciparum-infected erythrocytes. J. Immunol. 2002, 169:2956-2963.
133. Horowitz A., et al. Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. J. Immunol. 2010, 184:6043-6052.
134. Korbel D.S., et al. Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals. J. Immunol. 2009, 182:6426-6434.
135. Ndungu F.M., et al. Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathog. 2009, 5:e1000690.
136. Nduati E.W., et al. Distinct kinetics of memory B-cell and plasma-cell responses in peripheral blood following a blood-stage Plasmodium chabaudi infection in mice. PLoS ONE 2010, 5:e15007.
137. Nogaro S.I., et al. The breadth, but not the magnitude, of circulating memory B cell responses to P. falciparum increases with age/exposure in an area of low transmission. PLoS ONE 2011, 6:e25582.
138. Weiss G.E., et al. The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog. 2010, 6:e1000912.
139. Modiano D., et al. Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13206-13211.
140. Portugal S., et al. B cell analysis of ethnic groups in Mali with differential susceptibility to malaria. Malar. J. 2012, 11:162.
141. Ndungu F.M., et al. Memory B cells are a more reliable archive for historical antimalarial responses than plasma antibodies in no-longer exposed children. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:8247-8252.
142. + regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity 2005, 23:287-296.
143. Minigo G., et al. Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog. 2009, 5:e1000402.
144. Walther M., et al. Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparum malaria. PLoS Pathog. 2009, 5:e1000364.
145. Herrington D.A., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987, 328:257-259.
146. Patarroyo M.E., et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988, 332:158-161.
147. Wang R., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480.
148. Schofield L., et al. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418:785-789.
149. Jiang G., et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS ONE 2009, 4:e6559.
150. + T cell immunity. Science 2011, 334:475-480.
151. Purcell L.A., et al. Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice. Infect. Immun. 2008, 76:1193-1199.